Enrolling Now: Phase 2 trial to evaluate the safety and efficacy of SPR001 in adults with classic CAH

If you are an adult with a genetic diagnosis of classic Congenital Adrenal Hyperplasia, you may be eligible to participate in a Phase 2 clinical trial for a new therapy for CAH.

The Phase 2 clinical trial will test the safety and efficacy of a pill for Congenital Adrenal Hyperplasia. To learn more, and see if you may qualify, go to www.CAHclinicaltrial.com

Congenital Adrenal Hyperplasia Clinical Trials 2019

Spruce also has ongoing collaborations with the National Institutes of Health (NIH) for longer duration study of the safety and efficacy of tildacerfont in adults 18+.
Learn More
 
If you are age 12+ and diagnosed with Congenital Adrenal Hyperplasia, we invite you to join our Natural History Study and Registry.

The CAH Natural History Study's mission is to learn more about CAH so researchers can work to improve the quality of life and the health of individuals with CAH, and to provide hope through the promise of new treatments.

Learn more

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. We are leveraging our extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from these diseases. We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.